Novavax to Participate in Jefferies London Healthcare Conference

Novavax (Nasdaq: NVAX) will participate in the Jefferies London Healthcare Conference with a fireside chat on November 17, 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Novavax (Nasdaq: NVAX) will participate in the Jefferies London Healthcare Conference with a fireside chat on November 17, 2026.

The chat in London, United Kingdom, starts at 5:00 p.m. GMT. A live webcast will be available on the Events & Presentations page at ir.novavax.com, with a replay available for 30 days following the presentation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/11/2026 - 05:00 PM EST

GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference:

Jefferies London Healthcare Conference, London, United Kingdom
Fireside chat on Tuesday, November 17, 2026, at 5:00 p.m. GMT

A live webcast of the fireside chat will be available on the "Events & Presentations" page of the Company's website at ir.novavax.com. A replay of each webcast will be available for 30 days following the presentation.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M^® adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, capital-efficient research and development (R&D) innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid™, R21/Matrix-M™), Matrix technology and research and development assets. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors
Naina Zaman
240-410-5353
ir@novavax.com

Media
Yvonne Sprow
240-720-7804
media@novavax.com